The protein alpha-synuclein whose expression is strongly implicated in Parkinson's disease (PD) is not only expressed in the CNS but also in the enteric nervous system (ENS). The growing body of evidence suggesting that gastrointestinal inflammation is involved in the development of PD led us to investigate the effects of inflammation on alpha-synuclein expression in primary culture of rat ENS and in mice with dextran sulfate sodium-induced colitis. Using western blot and qPCR, we found that both lipopolysaccharide and a combination of tumor necrosis factor-a and interleukin 1-b decreased the expression levels of alpha-synuclein in primary culture of rat ENS, an effect that was prevented in the presence of the p38 inhibitors SB203580 and BIRB 796. Lipopolysaccharide and tumor necrosis factor-a/interleukin 1-b had no effect on alpha-synuclein expression in primary culture of rat CNS and in human erythroid leukemia cells. In mice, acute but not chronic dextran sulfate sodium-induced colitis was associated with a decreased expression of colonic alpha-synuclein. As a whole, our findings indicate that acute inflammatory insults down-regulate alpha-synuclein expression in the ENS via a p38 pathway. They provide new insights into the widely discussed concepts of alpha-synuclein expression and aggregation in the ENS in PD and raise issues about the possible role of gastrointestinal inflammation in the development of PD.
The protein alpha-synuclein is linked both genetically and neuropathologically to Parkinson's disease (PD). Missense mutations of alpha-synuclein are responsible for autosomal dominant forms of PD (Polymeropoulos et al. 1997; Kr€ uger et al. 1998; Zarranz et al. 2004) and Lewy bodies and neurites, the defining neuropathological characteristics of the disease, are primarily composed of aggregated alphasynuclein (Spillantini et al. 1997 ). In addition, there is now a large body of evidence implicating the expression levels of alpha-synuclein in PD. Both duplications and triplications of the alpha-synuclein gene have been identified in familial forms of the disease (Singleton et al. 2003; Chartier-Harlin et al. 2004; Ib añez et al. 2004 ) and analysis of brain from sporadic PD subjects showed higher expression of alpha-synuclein mRNA compared to controls (Gr€ undemann et al. 2008) . Overall, these findings indicate that the mere over-expression of alpha-synuclein is sufficient to cause genetic PD, and that a subtle alteration of alpha-synuclein expression may be critically involved in the development of sporadic cases of the disease (Devine et al. 2011 ).
An accumulating body of literature has emerged in the past 25 years to show that PD is not only disorder of the brain but also of the gastrointestinal (GI) tract and more generally speaking of the brain-gut axis (Lebouvier et al. 2009; Derkinderen et al. 2011) . GI symptoms occur in almost every PD patient at some point (Edwards et al. 1992 ) and autopsy studies have consistently shown that alpha-synuclein aggregates are found in the enteric nervous system (ENS) in nearly every case examined pathologically (Wakabayashi et al. 1988; Beach et al. 2010; Gelpi et al. 2014) . Why alpha-synuclein accumulates in the enteric neurons is still debated, but numerous findings support a role for local inflammation. Two studies conducted in rodents suggest that gut microbial-induced inflammation may foster alphasynuclein expression/aggregation, one through production of lipopolysaccharide (LPS) (Choi et al. 2018) , the other via bacterial amyloid and cross seeding (Chen et al. 2016) . A recent study reported more alpha-synuclein immunostaining in duodenal biopsies from pediatric patients with upper-GI tract inflammation (Stolzenberg et al. 2017) . Regarding PD, higher expression levels of colonic pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-a) and interleukin 1-beta (IL1-b) (Devos et al. 2013) as well as elevated fecal markers of inflammation (Houser et al. 2018; Schwiertz et al. 2018 ) have been observed in PD patients when compared to controls. The potential role of GI inflammation in the development of PD is further reinforced by the results of two large cohort studies, which showed a significant association between inflammatory bowel disorders and the subsequent occurrence of PD (Peter et al. 2018; Villumsen et al. 2018) .
As a whole, these observations support the assumption that inflammation might regulate enteric alpha-synuclein expression and therefore we set out to examine the regulation of alpha-synuclein expression in vitro in rat primary culture of ENS and in vivo in a mouse model of colitis.
Material and methods

Cell culture
Primary cultures of rat ENS were generated and cultured as previously described (Coquenlorge et al. 2014) . Briefly, small intestine of rat embryos E15 (20-28 per isolation from two pregnant Sprague-Dawley rats (Janvier Laboratories SA, Le Genest-St-Isle, France) were removed and finely diced in Hanks' Balanced Salt Solution (Sigma, Saint Quentin Fallavier, France, Cat# H9259). Tissue fragments were collected in 8 mL of Dulbecco's modified Eagle medium (DMEM-F12) (1 : 1) (Gibco, Life Technologies, Cergy-Pontoise, France, Cat# 31330-038) and digested at 37°C for 15 min in 0.1% (w/v) trypsin (Sigma, Cat# T1426). The trypsin reaction was stopped by adding 20 mL of medium containing 10% (v/v) fetal bovine serum (Sigma, Cat# F2442) and then treated by 0.01% (w/v) DNAse I (Sigma, Cat# DN25) for 10 min at 37°C. After trituration with a 10 mL pipette, cells were centrifuged at 750 rpm for 10 min. Cells were counted and then seeded at a density of 2.4.10 5 cells/cm² on 24-well plates previously coated for 2 h with a solution of 0.5% (w/v) gelatin (Sigma, Cat# G6144) in sterile phosphate-buffered saline (PBS) (Gibco, Life Technologies, Cat# 10010023). After 24 h, the medium was replaced with a serum-free DMEM-F12 (1 : 1) medium containing 1% (v/v) of N-2 supplement (Life Technologies, Cat# 17502-048). Cells were maintained in culture for 17 days. For primary culture of CNS cortical neurons, cortex of rat embryos E15 was dissociated mechanically and digested at 37°C for 15 min in 0.1% (w/v) trypsin (Sigma, Cat# T1426). The trypsin reaction was stopped by adding DMEM-F12 (1 : 1) medium (Gibco, Life Technologies Cat# 31330-038) containing 10% (v/v) fetal bovine serum (Sigma, Cat# F2442) and then treated by 0.01% (w/v) DNAse I (Sigma, Cat# DN25) for 10 min at 37°C. After trituration with a 10 mL pipette, cells were centrifuged at 750 rpm for 10 min. Cells were counted and then seeded at a density of 150 000 cells per well on 24-well plates previously coated for 2 h with a solution of 0.5% (w/v) gelatin (Sigma, Cat# G6144) in sterile PBS (Gibco, Life Technologies, Cat# 10010023).
Human erythroid leukemia cells (HEL 92.1.7; ATCC Cat# TIB-180, research resource identifier, RRID#CVCL_2481; LGC Standards, Molsheim, France) were cultured in RPMI 1640 (Sigma, Cat# 21875-034) supplemented with 10% (v/v) fetal bovine serum, 50 units/mL penicillin, and 50 lg/mL streptomycin (Life Technologies, Cat#15140-122) at densities from 0.2 to 1.5.10⁶ cells/mL. This cell line is not listed as a commonly misidentified cell line by the International Cell Line Authentication Committee and was authenticated in June 2017.
DSS-induced colitis
Two different models of colon inflammation were studied in male C57BL/6NRJ (8 weeks, Janvier) mice. Acute colitis was induced by 4% (w/v) Dextran Sulfate Sodium (36-50 000 kDa; MP Biomedicals, Illkirch, France, Cat# ICN216011080) in the drinking water for 4 days, while chronic colitis was obtained by three cycles of 2% (w/v) DSS in drinking water for 2 days followed by 5 days of water. The corresponding control groups of animals were treated with regular water for the same period. For acute colitis experiments, controls and DSS-treated mice were killed by cervical dislocation on days 1, 2, 3, and 4 (n = 5 per group). For chronic colitis experiments, controls and DSS-treated mice were killed on day 18 (n = 10 per group). Samples of transverse and distal colon were taken and stored at À80°C in lysis buffer RA1 (Macherey-Nagel, Hoerdt, France, Cat# 740961.500) for further analysis by PCR and western blot. No randomization was performed.
All housing and experimental procedures for mice and pregnant rats were carried out in compliance with the local ethical review panel of INSERM (agreement E. 44011; INSERM, Nantes, France) and in accordance with the Council Directive 2010/63EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes. Animals were housed in standard 42 9 26 9 15 cm plastic cages. Bedding consisted of kiln-dried aspen shavings (SAFE, Augy, France). Water and food were available (SAFE) ad libitum. Animals were housed at 19-22°C, humidity 55%, and 12 : 12 h light: dark cycle with lights on at 07:30.
Treatment of cells
After 14 days in vitro, cells were treated with LPS (Sigma, Cat#L2630), TNF-a (Sigma, Cat#T6674), interleukin 1-b (Sigma, Cat#I9401), interleukin-6, interleukin-10, interferon-c (Preprotech, Neuilly-sur-Seine, France, Cat#200-06, 200-10, and 300-02 respectively), SB 203580 (Merck, Calbiochem, Fontenay sous bois, France, Cat#559395), BIRB 796 (Tocris, Lille, France, Cat#5989), and 6o (Tocris, Cat# 3222) for the indicated period of time.
Western blot
Cells were harvested and lysed in radioimmunoprecipitation assay buffer (Merck Millipore, Fontenay sous Bois, France, Cat# 20-188) containing 2 mM orthovanadate (Sigma, Cat# S6505), phosphatase inhibitor cocktail II (Sigma, Cat# P5726), and a protease inhibitors cocktail (Sigma, Cat# 11697498001). Colonic samples stored in RA1 buffer were lysed with the 'Precellys 24' tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France, Cat# P000669-PR240-A) and total proteins were precipitated using protein precipitator and re-suspension buffer (protein solving buffer and tris(2-carboxyethyl)phosphine-reducing agent) from NucleoSpin Triprep Kit (Macherey-Nagel, Hoerdt, France, Cat# 740966) according to the manufacturer's instructions. Samples were further prepared for electrophoresis by diluting with NuPAGE sample buffer (Life Technologies, Saint-Aubin, France, Cat# NP0008) then heated at 98°C for 5 min. Lysates were separated using the NuPAGE 4-12% Bis-Tris gels (Life Technologies, Cat# NP0336BOX) together with the 2-(N-morpholino)ethanesulfonic acid/sodium dodecyl sulfate running buffer (Life Technologies, Cat# IB23002) before electrophoretic transfer to nitrocellulose membranes (Life Technologies, Cat# NP0002) with the iBlot TM Dry Blotting System (Life Technologies, Cat# IB21001). Nitrocellulose membranes were treated with 4% (v/v) paraformaldehyde and 0.01% (v/v) glutaraldehyde (Cat#G6257, Sigma) in order to enhance membrane retention of alpha-synuclein (Sasaki et al. 2015) . Membranes were then blocked for 1 h at 21°C in Tris-buffered saline (Sigma, Cat# T5912) with 0.1% (v/v) Tween-20 (Sigma, Cat# P1379) and 5% (w/v) non-fat dry milk and incubated overnight at 4°C with the following primary antibodies: rabbit polyclonal anti-alpha-synuclein (C-20)-R (1 : 1000; Santa Cruz Biotechnology, Heidelberg, Germany, Cat# sc-7011-R, RRID: AB_2192953), mouse monoclonal anti-alpha-synuclein Syn-1 (1 : 1000; BD Bioscience, Le Pont-de-Claix, France, Cat# 610787, RRID:AB_398108), mouse monoclonal anti-PGP 9.5 (1 : 2000; Thermo Fischer Scientific, Saint Herblain, France, Cat# MA1-83428, RRID:AB_935198), mouse monoclonal anti-b-actin (1 : 10000; Sigma, Cat#A5441, RRID:AB_476744) rabbit polyclonal antiphospho-p38, -phospho-JNK, -p38, and -JNK (1 : 1000; Cell signaling, Ozyme, Saint Quentin en Yvelines, France Cat#9211, 9251, 9212, and 9252; RRID:AB_331641, AB_331659, AB_330713, AB_2250373, respectively), and mouse monoclonal anti-toll-like receptor 4 (TLR4) (Novus, Bio-Techne, Lille, France, Cat# NB100-56566, RRID:AB_2205129). Bound antibodies were detected with horseradish peroxidase-conjugated anti-rabbit (Life Technologies Cat# 31460, diluted 1 : 5000) or anti-mouse antibodies (Sigma, Cat# A9044, diluted 1 : 5000) and visualized by enhanced chemiluminescent detection (Biorad, Clarity ECL, Marnes-la-Coquette, France, Cat# 170-5061). For quantification, the relevant immunoreactive bands were quantified with laser-scanning densitometry and analyzed with NIH Image J software (Bethesda, MD, USA) (version 1.51). To allow comparison between different films, the density of the bands was expressed as a percentage of the average of controls. The value of alphasynuclein immunoreactivity was normalized to the amount of PGP 9.5, while phospho-p38 and -JNK immunoreactivity were normalized to p38 and JNK immunoreactivity, respectively.
Quantitative PCR analysis RNA extraction from enteric primary culture was performed with RNAeasy Minikit (Qiagen S.A., Courtaboeuf, France, Cat# 74104) according to the manufacturer's instructions. The following primers were used:
For colonic tissues stored in RA1 buffer, RNA extraction was performed with NucleoSpin Triprep Kit (Macherey-Nagel, Hoerdt, France, Cat# 740966) according to the manufacturer's instructions. One lg purified mRNA was denatured and processed for reverse transcription using Superscript III reverse transcriptase (Thermo Fisher Scientific, Saint-Herblain, France, Cat # 18080044). PCR amplifications were performed using the Absolute Blue SYBR green fluorescein kit (Roche Molecular Biochemicals, Meylan, France, Cat# AB4166B) and run on a StepOnePlus system (Life Technologies, Cat# 4376600). The following primers were used:
• TNFa # NM_013693.3, forward: 5
Immunohistochemistry
Primary culture of rat ENS was fixed in PBS with 4% (v/v) paraformaldehyde at 21°C for 30 min. Following pre-incubation in PBS containing 5% (v/v) donkey serum and 0.5% (v/v) Triton TM X-100 (Sigma, Cat # X100) for 30 min, cells were incubated with the following primary antibodies overnight at 4°C: mouse monoclonal anti-alpha-synuclein Syn-1 (1 : 1000; BD Bioscience, Cat# 610787), rabbit monoclonal anti-rat alpha-synuclein D37A6 (1 : 500; Cell Signaling Ozyme, Saint Quentin en Yvelines, France, Cat#4179, RRID:AB_1904156), mouse monoclonal anti-HuC/D (1 : 200; Life Technologies, Cat#A21-271, RRID:AB_221448), mouse monoclonal anti-b-tubulin III (1 : 1000; Sigma, Cat# T8328, RRID:AB_1844090), rabbit polyclonal anti-S100b (1 : 1000; Agilent, Dako Omnis, Courtaboeuf Les Ulis, France, Cat# GA50461-2), mouse monoclonal anti-TLR4 (1 : 1000, Novus, Cat# NB100-56566, RRID:AB_2205129), and goat polyclonal anti-a-smooth muscle actin (1 : 500; Abcam, Paris, France, Cat# ab21027). After secondary antibodies, images were acquired with an Olympus IX 50 fluorescence microscope.
Cell viability and neuronal damage assays Evaluation of neuronal damage was performed using neuronspecific enolase (NSE) release into the culture medium and counting of Hu-immunoreactive neurons. NSE released in the culture supernatant was quantified using a rat NSE ELISA kit (MyBioSource, Catalog #MBS2508955; CliniSciences, Nanterre, France) according to the manufacturer's protocol. Results were expressed in nanograms per mL. The total number of HuC/HuDimmunoreactive neurons was counted in the entire culture well treated by LPS and TI and expressed as percentage of the number of total neurons in control wells (see immunohistochemistry).
Cell viability was assessed using the Celltiter 96 Aqueous nonradioactive cell proliferation 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium assay (Promega, Charbonni eres-les-Bains, France, Cat#G3582). Primary culture of rat ENS was cultured in 12-well plates and treated as described above. After removal of the medium, CellTiter 96 Aqueous One Solution reagent was added to each well, according to the manufacturer's instructions. Neuronal viability was determined by measuring absorbance at 490 nm.
Filter trap assay
Ten micrograms of cell lysates was subjected to vacuum filtration through a 96-well dot blot apparatus (Bio-Rad, Marnes-la-Coquette, France, Cat#1706545) with 0.45 lm pore size cellulose acetate membranes (Sterlitech, Kent, OH, USA, Cat#CA0453001). Samples of frozen temporal cortex from one post mortem human brain with dementia with Lewy bodies were obtained from the Neuropathology Department of Angers (Dr Franck Letournel) and were processed in the same way to serve as a control. The resultant membranes were processed as indicated in the western blot section using rabbit monoclonal anti-human alpha-synuclein MJFR1 (1 : 1000; Abcam, Cat# ab138501, RRID:AB_2537217) for dementia with Lewy bodies samples or rabbit monoclonal anti-rat alpha-synuclein D37A6 (1 : 500; Cell-Signaling, Cat#4179, RRID:AB_1904156) antibodies for cell lysates.
Statistics
GraphPad Prism software version 7.05 (GraphPad Software Inc., La Jolla, CA, USA) was used for statistical analysis. Because data were not normally distributed according to the Kolmogorov-Smirnov test, we used non-parametric tests. The differences between groups were calculated by a Mann-Whitney U-test. The effects of SB203580 on LPS-and TI-induced down-regulation of alphasynuclein in western blots were analyzed with a Kruskal-Wallis non-parametric ANOVA test, followed by Dunn's post hoc test. No sample size calculation and no blinded analysis were performed. No test for outliers was conducted on the data.
Results
Alpha-synuclein is expressed by neurons in primary culture of rat ENS After 17 days of culture, enteric neurons (Hu immunostaining, Fig. 1a) were organized in ganglia connected to each other by interganglionic fiber strands as demonstrated by b-tubulin III immunostaining (Fig. 1b) . Enteric glial cells, identified by S100-b immunostaining, were also present in enteric ganglia and along interganglionic fiber strands (Fig. 1a and c) . This neuronal network laid on a smooth muscle cells monolayer (Fig. 1a) . Immunolabelling with two different anti-alphasynuclein antibodies revealed that alpha-synuclein was present in the cytoplasm of the soma of enteric neurons (Fig. 1b and Figure S1 ). A subset of enteric neurons expressed alphasynuclein in both the nucleus and the cytoplasm of the soma (Fig. 1b and Figure S1 ). By contrast, alpha-synuclein was not expressed by enteric glial cells (Fig. 1c) .
LPS and TNF-a/IL1-b decrease the expression levels of alpha-synuclein in primary culture of ENS Primary culture of rat ENS expresses the LPS receptor TLR4 (Coquenlorge et al. 2014) (Figure S2a and b) as well as the receptors for TNF-a and IL1-b (Gougeon et al. 2013) . To determine whether inflammation alters alpha-synuclein expression, we treated primary culture of rat ENS with 0.1 lg/mL LPS and a combination of two pro-inflammatory cytokines TNF-a and IL1-b (TNF-a/IL1-b, 10 nM each, hereafter referred to as TI) for 72 h. Such concentrations of LPS, TNF-a, and IL1-b were not neurotoxic in previous reports that used cultured ENS (Gougeon et al. 2013; Coquenlorge et al. 2014; Voss and Ekblad 2014) . Cell lysates were analyzed by western blot with two anti-alpha-synuclein antibodies [(C20)-R and Syn-1] that recognize different epitopes (Perrin et al. 2003; Preterre et al. 2015) . Both TI and LPS caused a significant decrease in the amount of alphasynuclein in primary culture of ENS ( Fig. 2a and b) . We verified that both treatments did not affect cell viability, as determined by measurement of NSE release into the culture medium, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium assay, and counting of Hu-immunoreactive cells (Fig. 2c) . The decrease in alpha-synuclein protein in response to LPS and TI was accompanied by a significant down-regulation at the mRNA level (Fig 2d) . Treatment with either LPS or TI did not induce alpha-synuclein aggregation (Fig 2e) and did not change the subcellular localization of alpha-synuclein ( Fig. 1b and Figure S1) . By contrast to TNF-a and IL1-b, other proinflammatory cytokines including interleukins-6 and -10 and interferon-c had no significant effects on alpha-synuclein expression (Fig. 2f) .
The effects of LPS and TI on alpha-synuclein expression are mediated through a p38 signaling pathway Both JNK and p38 signaling pathways are strongly activated by inflammatory mediators in numerous cell types (Hotamisligil and Davis 2016) . To determine the respective role of these two signaling pathways on alphasynuclein expression, we used antibodies specific for the dually phosphorylated active forms of p38 and JNK together with specific inhibitors of these two kinases. TI caused a rapid and transient activation of p38 in primary culture of ENS (Fig 3a) , while LPS induced a more delayed and more sustained activation of the kinase (Fig. 3b) . To further investigate the role of p38 signaling pathway in alpha-synuclein expression, we used two different structurally unrelated p38 inhibitors SB 203580 (Cuenda et al. 1995) and BIRB 796 (Pargellis et al. 2002) . We first evaluated the efficacy of these two compounds in primary culture of ENS by showing that they efficiently decreased the phosphorylation of the p38 downstream target heat-shock protein 27 ( Figure S4 ). Treatment with SB 203580 (10 lM) or BIRB 796 (1 lM) for 72 h induced a significant increase in the expression levels of alphasynuclein ( Fig. 3c and d) . Treatment with SB 203580 fully reversed the TI-and LPS-induced down-regulation of alpha-synuclein (Fig. 3e ). TI and LPS had only a marginal effect on JNK phosphorylation ( Figure S3a and b) and no change in alpha-synuclein expression levels was observed following JNK inhibition by 6o ( Figure S3c ).
LPS and TI have no effects on alpha-synuclein expression in primary CNS neurons and HEL cells
In order to determine whether the effects of LPS and TI on alpha-synuclein expression are specific to enteric neurons, we used primary culture of rat CNS neurons and human erythroleukemia (HEL) cell line, which both constitutively express alpha-synuclein (Dettmer et al. 2013; Corbill e et al. 2016) . No changes in the expression levels of alpha- synuclein were observed after a 72 h-treatment with either LPS or TI in these two cell types ( Fig. 4a and b) . In addition, and by contrast to primary culture of rat ENS, treatment of primary CNS neurons and HEL cells with SB 203580 had no effect on alpha-synuclein expression (Fig. 4c and d and Figure S4 ). Fig. 2 Effects of lipopolysaccharide (LPS) and pro-inflammatory cytokines on the expression of alpha-synuclein in primary culture of rat enteric nervous system (ENS). (a and b) After 14 days in culture, primary culture of rat ENS was treated with vehicle (phosphate buffer saline, control), 0.1 lg/mL LPS, or 10 nM TI for 72 h. Cell lysates were subjected to immunoblot analysis using two different antibodies specific for alpha-synuclein (C20-R and Syn-1). Membranes were probed with anti-PGP9.5 antibodies to ensure equal loading of neuronal proteins. Values represent mean AE SEM (n = 8 and 14 per condition for LPS and TI, respectively; treated vs. control *p < 0.05; **p < 0.01). (c) Cell survival and viability were evaluated by measuring the release of neuron-specific enolase in the culture medium (left, in ng/mL), performing an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium assay (middle, expressed as percentage of controls) and by Hu neuronal counting (right, expressed as percentage of controls). Three representative Hu staining are shown, scale bar 25 lm). Values represent mean AE SEM (n = 4, 12, and 6, respectively). (d) Quantitative PCR analysis of alphasynuclein mRNA in primary culture of rat ENS treated after 14 days in vitro with vehicle (control), LPS, or TI for 24, 48, or 72 h. Values represent mean AE SEM (n = 10-20 samples per condition; treated vs. control *p < 0.05; **p < 0.01). (e) Lysates from primary culture of ENS treated with LPS, TI, and vehicle (control) for 72 h were subjected to filter trap assay analysis with cellulose acetate membrane using antirat alpha-synuclein D37A6 antibody. Samples from dementia with Lewy bodies brain served as control and were analyzed with antihuman alpha-synuclein MJFR1 antibody. Data shown are representative of four independent experiments. (f) After 14 days in culture, primary culture of rat ENS was treated with vehicle (control), 10 nM interleukin-6 (IL-6), IL-10, and interferon-c (IFN-c) for 72 h. Cell lysates were subjected to immunoblot analysis and quantification was performed as described in (a) (n = 4). IB is for immunoblot.
Acute but not chronic DSS-induced colitis is associated with a decreased expression of alpha-synuclein To determine whether inflammation impacts alpha-synuclein expression in vivo, we used two models (acute and chronic) of DSS-induced colitis in mice. The colonic proinflammatory cytokines expression profile for each model is shown in Figure S5 . In the acute/severe model of colitis, which was induced by a 4-day 4% DSS regimen, we observed a significant decrease in the expression levels of alpha-synuclein in the distal colon at day 1 and day 3 Fig. 3 Roles of the p38 signaling pathway on lipopolysaccharide (LPS)-and tumor necrosis factor-a/interleukin 1-b-induced downregulation of alpha-synuclein. (a and b) After 14 days in culture, primary culture of rat enteric nervous system (ENS) was treated with vehicle (control), with TI for 5, 15, 30, and 60 min or with LPS for 15, 30, 60, 180, and 480 min. Cell lysates were subjected to immunoblot analysis using antibodies specific for the dually phosphorylated (active) forms of p38 (℗-p38). After stripping the membranes were reprobed with total p38 antibody. The values of active phospho-p38 were normalized to the amount of total p38. Values represent mean AE SEM (n = 4-8 samples per condition; treated vs. control *p < 0.05; **p < 0.01). (c) Primary culture of rat ENS was treated with vehicle (control) or 10 lM of the p38 inhibitor SB203580 for 72 h and cell lysates were subjected to immunoblot analysis with anti-alphasynuclein antibody (C-20)-R. Values represent mean AE SEM (n = 15; treated vs. control **p < 0.01). (d) Primary culture of rat ENS was treated with vehicle (control) or 1 lM of the p38 inhibitor BIRB 796 for 72 h and cell lysates were subjected to immunoblot analysis with antialpha-synuclein antibody Syn-1. Values represent mean AE SEM (n = 8; treated vs. control *p < 0.05). (e) Primary culture of ENS was treated with either LPS or TI for 72 h in the absence (À) or presence (+) of 10 lM SB203580 and cell lysates were subjected to immunoblot analysis with anti-alpha-synuclein antibody Syn-1. Values represent mean AE SEM (n = 8-14; treated vs. control *p < 0.05; treated in the presence of SB203580 vs. in its absence: # p < 0.05). IB is for immunoblot.
( Fig. 5a ) when compared to control animals (a trend approaching but not reaching significance was observed at days 2 and 4, data not shown). By contrast, when a more chronic model of colitis (three cycles of 2% DSS for 2 days followed by 5 days of water) was used, no changes in the expression levels of alpha-synuclein were observed between treated and control animals.
Discussion
Despite the growing evidence linking inflammation to PD development, very few studies have directly examined the effects of inflammatory mediators on alpha-synuclein expression in cell lines (Tanji et al. 2001 ) and our study is the first performed in enteric neurons. We show that both LPS and TI down-regulate alpha-synuclein expression at both mRNA and protein levels in primary culture of rat ENS, but not in primary culture of rat cortical neurons and in HEL cells. It is unlikely that the lack of effects in CNS neurons and erythroid cells is due to an absence of receptors, as current and previous observations have shown that both cell types express functional TLR4, TNF, and interleukins receptors (Inoue et al. 2006; Wang et al. 2013) . One possible explanation may be that the enteric glia and smooth muscle cells, which are present in cultured ENS may contribute to the LPS-and TI-induced phenotypes in non-cell autonomous ways. Another explanation might come from intrinsic differences between the neuron subtypes. In an elegant article, Rideout et al. compared the regulation of alphasynuclein levels between different subtypes of rat primary CNS neurons and showed that basic fibroblast growth factor promoted alpha-synuclein expression within dopaminergic, but not GABAergic or cortical neurons (Rideout et al. 2003 ). An increase in intracellular cAMP, either induced by nonhydrolyzable analogs or by b2 adrenoreceptor activation, down-regulated alpha-synuclein in PC12 and human neuroblastoma cell line (Stefanis et al. 2001; Mittal et al. 2017) , while an opposite effect was observed in primary ENS culture (Paillusson et al. 2010) . Such a specific regulation of alpha-synuclein might be relevant in the context of PD as the disruption of transcriptional regulation in different neuronal populations could underlie the clinical and neuropathological heterogeneity observed in this neurodegenerative disorder (Leclair-Visonneau et al. 2018) . So far, most existing studies on alpha-synuclein expression in neurons have identified the extracellular signal-regulated kinases (ERK) pathway as being a key player. The induction of alpha-synuclein by growth factors in PC12 cells is ERK dependent (Clough and Stefanis 2007) as is the regulation of alpha-synuclein expression by neuronal activity in cultured ENS (Paillusson et al. 2010) . We show in this study that the p38 signaling pathway is also critically involved in the regulation of alpha-synuclein expression in enteric neurons. By contrast to primary cortical neurons, two different p38 inhibitors dramatically increased the expression levels of alpha-synuclein in primary culture of ENS, thereby suggesting that the amount of alpha-synuclein is tonically downregulated in enteric neurons via a p38 signaling pathway. In addition, we showed that the effects of either TI or LPS on enteric alpha-synuclein expression were completely reverted in the presence of the p38 inhibitor SB203580. Our current results, together with our previous findings (Paillusson et al. 2010) , indicate that the ERK inhibitor U0126 and the p38 inhibitor SB203580 have an opposite effect on alphasynuclein expression in primary culture of ENS, inducing a down-and up-regulation of alpha-synuclein, respectively. They therefore strongly support the existence of a cellular signaling network in enteric neurons in which alphasynuclein expression level is regulated by a cross-talk between ERK and p38.
In order to extend our results obtained in vitro, we studied the expression levels of alpha-synuclein in the colon of mice with DSS-induced acute colitis. Acute, chronic, and relapsing models of intestinal inflammation can be achieved by modifying the concentration of DSS as well as the frequency of administration and clinical signs of disease appear as soon as 1 day post-treatment, with an increased expression of the main pro-inflammatory cytokines (Yan et al., 2009) . In agreement with our results obtained in vitro, we observed a decreased expression of alpha-synuclein in the acute model of DSS-induced acute colitis. By contrast, when a more chronic administration regimen was used, we did not observe any change in the alpha-synuclein levels. Such a discrepancy might be explained by the lower levels of colonic proinflammatory cytokines that were found in this model when compared to the acute regimen (Garrido-Gil et al. 2018 ). These observations further reinforce the possible role of proinflammatory cytokines and especially TNF-a and IL1-b in Lysates from colonic samples from day 1 to day 4 were subjected to immunoblot analysis using Syn-1, PGP 9.5 and betaactin antibodies. Values represent mean AE SEM (n = 5 per condition and per day; treated vs. control *p < 0.05). (b) Chronic colitis was obtained by three cycles of 2% DSS in drinking water for 2 days followed by 5 days of water. Lysates from colonic samples at day 18 were subjected to immunoblot analysis using Syn-1, PGP 9.5 and beta-actin antibodies. Values represent mean AE SEM (n = 10 per condition).
the regulation of enteric alpha-synuclein level. In further experiments, it will be interesting to study if alpha-synuclein is up-regulated in a model of slowly progressive colitis that can be induced by administering 4-5 repeated cycles of DSS.
At first glance, our results seem at odds with two recently published studies that reported an increase in alphasynuclein levels in humans with either acute or chronic GI inflammation (Stolzenberg et al. 2017; Prigent et al. 2018) . In children who received intestinal transplant, norovirus virus infection induced a marked and persistent elevation in alpha-synuclein in the upper-GI tract (Stolzenberg et al. 2017) . We recently showed that the expression levels of alpha-synuclein is increased in patients with chronic inflammatory disorders of the GI tract, such as Crohn's disease (Prigent et al. 2018) . A possible explanation for the discrepancy between these results and our current findings may be related to the mechanisms involved in the regulation of alpha-synuclein levels in each model. As suggested by Stolzenberg et al. (2017) , the greater amount of alphasynuclein observed in the mucosa of norovirus-infected children likely results from a mobilization of the protein within the ENS, which is part of a normal immune defense mechanism. Regarding Crohn's disease, our unpublished results suggest that the up-regulation of alpha-synuclein is not transcriptionally mediated but is instead due to a decrease in protein degradation.
On the basis of increasing evidence showing that PD patients exhibit inflammation in the gut (Devos et al. 2013) , several authors have proposed a model for PD pathogenesis. In such a model, an hitherto unknown pathogen triggers intestinal inflammation, which in turn would induce intestinal hyperpermeability, to increase the expression and aggregation of alpha-synuclein in neurons of the submucosal plexus whose terminal axons are only micrometers away from the gut lumen (Lema Tom e et al. 2013; Houser and Tansey 2017) . The pathological process would further spread to the CNS via the vagal preganglionic innervation of the gut, as this has been already demonstrated for prion (Kujala et al. 2011 ) and neural tracers (Walter et al. 2009 ). In this context, our results suggest that if alpha-synuclein is up-regulated by GI inflammation in PD, it is not through a direct increase in protein synthesis. Therefore, at this time, it remains unclear whether the observed changes in inflammatory markers in PD patients are an initial occurrence that contributes to the development of the disease, or if they emerge in response to PD-related pathology in the enteric neurons or enteric glial cells (Beach et al. 2010; Clairembault et al. 2014) .
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